The annual meetings of the American Society of Clinical Oncology (ASCO) and the Euro­pean He­ma­tol­ogy Asso­ci­a­tion (EHA) took place earlier this month. The two meetings were attended by tens of thousands of physi­cians from around the world, and featured a myriad of oral pre­sen­ta­tions, posters, and e-abstracts summarizing the re­­sults of new on­col­ogy- and he­ma­tol­ogy-related re­search.

Included in the re­search pre­sented at the two meetings were more than 200 stud­ies discussing new mul­ti­ple myeloma-related findings.

In addi­tion to the two large meetings held earlier this month, the Inter­na­tion­al Myeloma Work­ing Group (IMWG) …

A session last Sunday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting featured a num­ber of poster pre­sen­ta­tions re­lated to mul­ti­ple myeloma.

During “poster sessions” at conferences such as the ASCO meeting, re­search re­­sults are made avail­able for review by meeting attendees in the form of posters, each of which summarizes the re­­sults of a single study. Each poster is typ­i­cally about two feet high by three or four feet in length, and all posters during a ses­sion are dis­played throughout a large conference hall.

Most of the myeloma-related …

There was an im­por­tant multiple myeloma-related presentation this Monday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

The presentation summarized early results of a pilot clin­i­cal trial being conducted at the University of Pennsylvania. The trial, which is scheduled to enroll 10 re­lapsed myeloma patients, is testing a promising ap­proach to cancer treat­ment known as “chimeric an­ti­gen re­cep­tor” (CAR) T-cell ther­apy.

CAR T-cell ther­apy has generated impressive results when used to treat certain kinds of leukemia and lym­phoma. These results have led to a concerted effort to use …

A poster session yesterday at the 2015 American Society of Clinical Oncology (ASCO) annual meeting was the venue for the first substantial dose of multiple myeloma-related presentations at the conference.

During the session, research results were made available for review by meeting attendees in the form of posters, each of which summarized the results of a single study. As is typically the case during such sessions, each poster was about two feet high by three or four feet in length. All posters were displayed throughout a large conference hall.

Most of the …

Updated results of a key Phase 1/2 trial testing the poten­tial new myeloma ther­a­py daratumumab were released this morning. The new results con­firm pre­vi­ous research indicating that single-agent dara­tu­mu­mab has notable activity as a multiple myeloma ther­apy.

Specifically, the results show that nearly one third of the trial par­tic­i­pants – who had received a median of five prior ther­a­pies – responded to single-agent dara­tumumab. The median time to disease pro­gres­sion was 3.7 months, and the esti­mated one-year over­all survival rate was 65 per­cent.

Daratumumab’s safety profile in the trial was …

The 51st annual meeting of the American Society of Clinical Oncology (ASCO) started earlier to­day, May 29, and will go through June 2 in Chicago.

Approximately 30,000 physicians and re­searchers from all over the world are ex­pec­ted to attend the five-day meeting to discuss cur­rent re­search in cancer treat­ment and care.

During the meeting, there will be pre­sen­ta­tions about all types of cancer, in­clud­ing many pre­sen­ta­tions focused spe­cif­i­cally on mul­ti­ple myeloma. In fact, more than 90 myeloma-related stud­ies are scheduled to be pre­sented, in one form or another, in con­nec­tion with the …